Anticancer Therapies – Products
SCF-c-Kit Signaling Axis: A Cancer Stemness Regulator
As a global leader in the recombinant technology, Sino Biological provides a diverse array of recombinant proteins, antibodies, and ELISA kits to facilitate research and development of cancer treatments that focus on c-Kit and other RTKs (EGFR, VEGFR, PDGFR, c-Met, TrkB, FGFR, and more).
OncoHost To Present PROphet® Biomarker Model That Accurately Predicts Clinical Benefit to ICI-Based Treatment
OncoHost has announced that it will give a poster presentation demonstrating the accuracy of its PROphet® biomarker model at the upcoming American Society of Clinical Oncology Annual Meeting, taking place June 2-6, 2023, in Chicago, Illinois.
Cell and Gene Therapy CDMO Targets North American Growth With Major US Acquisition
uBriGene, a cell & gene therapy contract development and manufacturing organization, is expanding into the US market with the acquisition of a state-of-the-art GMP manufacturing facility from NASDAQ-listed company Mustang Bio, Inc.
Efficient Transduction of CAR Into T Cells
AMSBIO announce a new range of high-titer Chimeric Antigen Receptor (CAR) lentivirus that provide high transduction efficiency with long-term, stable expression in resting and actively dividing cells.
Diving Deep Into Cell Therapy: An Industry Perspective
Active cell therapy drugs represent the latest in cancer treatment. Of these, chimeric antigen receptor (CAR) cell modalities are considered the most successful.
App Note / Case Study
CAR T: A Promising Cell Therapy for Cancer Treatment
CAR-T cell therapy has emerged as one of the most promising novel treatments in the fight against cancer.
Certis Oncology Solutions Announces Three Abstracts Accepted for Presentation at AACR Annual Meeting
Certis Oncology Solutions has announced that three abstracts have been accepted for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting.
Cantargia To host R&D Day on New Clinical Results of Nadunolimab in Pancreatic Cancer
Cantargia has announced it will host an R&D Day focusing on new clinical results and biomarker data for its lead asset, the IL1RAP-binding antibody nadunolimab, in pancreatic cancer patients.
CureSearch To Fund Phase I Clinical Trial for Pediatric Brain Cancer
CureSearch for Children’s Cancer has announced that it will fund a Phase I clinical trial to bring new therapies to pediatric brain cancer patients, including those with limited or no treatment options.
EpicentRx Receives Fast Track Designation From the U.S. FDA for Lead Asset
EpicentRx, Inc. has announced that the FDA has granted Fast Track Designation to RRx-001 for the prevention/attenuation of severe oral mucositis in chemotherapy and radiation-treated head & neck cancer patients.